Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 10, 2020
Daily News
January 10, 2020
- Sumitomo Dainippon’s Altavant Picks Up Onspira
January 10, 2020
- Chugai Licenses KRAS-Targeting Drug to Verastem
January 10, 2020
- Keytruda Remains Top-Seller in December Drug Ranking in Japan: Encise
January 10, 2020
- Hisamitsu Starts 2 PIII Studies for NSAIDs Patch, Plans Filing by February 2022
January 10, 2020
- Bristol-Myers Japan Chief Doubles as Celgene President amid Transition
January 10, 2020
- US District Court Dismisses Asahi Kasei’s Request for Continuing Supply of Xiaflex
January 10, 2020
- Meiji Gains Japan Rights for Novel Blood Cancer Treatment from HUYA Bioscience
January 10, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…